PolyMedix started clinical trials with HUGE doses
Post# of 72440
(Total Views: 668)
Posted On: 05/08/2018 11:25:59 PM
PolyMedix started clinical trials with HUGE doses of Brilacidin, which caused side effects like high blood pressure. Then they decided to pin all their hopes on one drug -- NOT Brilacidin -- because they had incurred huge debt and needed a success fast. Their drug failed.
Then CTIX (now IPIX) bought all their intellectual property for $5 million bucks. It was Dr. Menon's genius in recognizing that the Brilacidin dose was way too high, and re-doing the clinical trial with a much lower dose, that made it clear that the drug is both effective and safe.
Because the Brilacidin-ABSSSI clinical trial would take a very long time and something like $30 million dollars, IPIX management made the very smart decision to do faster and much cheaper clinical trials first, for Brilacidin-OM and Brilacidin-UP.
IPIX has avoided the problems that doomed PolyMedix -- taking on huge debt, and being so impatient for results that they used high doses of drugs that were unsafe. IPIX shareholders should be grateful that Dr. Menon and Mr. Ehrlich did NOT make these mistakes.
Then CTIX (now IPIX) bought all their intellectual property for $5 million bucks. It was Dr. Menon's genius in recognizing that the Brilacidin dose was way too high, and re-doing the clinical trial with a much lower dose, that made it clear that the drug is both effective and safe.
Because the Brilacidin-ABSSSI clinical trial would take a very long time and something like $30 million dollars, IPIX management made the very smart decision to do faster and much cheaper clinical trials first, for Brilacidin-OM and Brilacidin-UP.
IPIX has avoided the problems that doomed PolyMedix -- taking on huge debt, and being so impatient for results that they used high doses of drugs that were unsafe. IPIX shareholders should be grateful that Dr. Menon and Mr. Ehrlich did NOT make these mistakes.
(6)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼